Thursday, Feb 18, 1999

Preliminary Phase II Trial Results with Experimental Vascular Endothelial Growth Factor in Patients with Coronary Artery Disease are Disappointing

South San Francisco, Calif. -- February 18, 1999 --

"Based on the interesting biology of rhVEGF165, we are disappointed in the preliminary view of the data," said Susan D. Hellmann, M.D., M.P.H., Genentech's senior vice president, development and chief medical officer. "We will need to more fully analyze the data with our investigators to attempt to understand these results."

Genentech plans to meet with its rhVEGF165 investigators to determine next steps for the development of the molecule.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Eleven of the currently marketed biotechnology products stem from Genentech science, eight of which Genentech markets or promotes directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.

# # #